Search results
TIME100 Health: David Ricks
Time via AOL· 9 hours agoRicks is waiting for a decision from the FDA about its Alzheimer’s drug donanemab, a call the agency delayed this spring, citing the ...
Chiquita Brooks-LaSure
Time Magazine· 9 hours agoThe Centers for Medicare and Medicaid Services (CMS) has been both criticized—for its requirements for covering a new Alzheimer’s < ...
FDA Once Again Stands Athwart Biomedical Innovation, Yelling 'Stop!'
Reason.com via AOL· 3 days agoGrandbrothers | Dreamstime.com As earlier threatened, the Food and Drug Administration (FDA) has...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 14 hours agoAdditionally, towards the end of last year, Roche also bought Roivant’s ulcerative colitis drug, RG-6631 (RVT-3101), for the high price tag of $7.1bn....
FDA moves to regulate some tests it says may be unreliable
Anchorage Daily News· 3 days agoThe Food and Drug Administration has finalized a divisive plan to regulate laboratory medical tests...
How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
Yahoo Finance via AOL· 3 days agoNovo Nordisk is also conducting a trial for kidney disease. Eli Lilly, meanwhile, recently shared...
Eli Lilly Just Announced More Good News: Time to Buy?
Motley Fool via Yahoo Finance· 4 days agoEli Lilly's payouts are up 101.6% in the last five years. It's hard to find fault with this stock,...
Oasis Or Mirage? Digital Dementia Screening In The Neurology Desert
Forbes· 7 days agoIn my neurotech travels the most common companies I encounter are those building digital dementia screening tools. The number of people with Alzheimer’s ...
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Zacks via Yahoo Finance· 6 days agoAdjusted EPS is expected to be in the range of $15.00-$16.00. The Biogen stock rose following the...
Decoding Biogen Inc (BIIB): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 7 days agoOpportunities Market Expansion and Novel Drug Approvals: Biogen Inc is well-positioned to capitalize on new market opportunities, particularly with the...
